A Form 4 filed on November 9, 2026 discloses that Jennifer Lynne Fox, Chief Legal and Corporate Strategy Officer at Myriad Genetics Inc, was granted 139,267 time-based stock options on November 6, 2026 as a one-time retention award.

Key Highlights

  • Grant date: November 6, 2026, with an exercise price of $5.92 per share, equal to the closing price of Myriad Genetics common stock on that date.
  • Award size: 139,267 non-qualified stock options, all classified as a derivative security with direct ownership.
  • Vesting schedule: The options vest in full on November 6, 2029, subject to Fox's continued service through that date.
  • Expiration date: November 6, 2036, according to the filing.
  • Plan source: The grant was made under Myriad Genetics' 2026 Employee, Director and Consultant Equity Incentive Plan.
  • Price of derivative security: Listed as $0 in the filing.
  • Beneficial ownership following transaction: 139,267 derivative securities held directly.

Myriad Genetics Issues Retention Option Grant to Chief Legal Officer Fox

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Jennifer Lynne Fox, identified in the filing as Chief Legal and Corporate Strategy Officer of Myriad Genetics Inc (NASDAQ:MYGN), received a one-time non-qualified stock option grant on November 6, 2026. The filing describes the award as a retention grant made under the company's 2026 Employee, Director and Consultant Equity Incentive Plan.

The filing states that the exercise price of $5.92 per share equals the closing price of the issuer's common stock on November 6, 2026, the grant date. The options become exercisable in full on November 6, 2029, described in the filing as a cliff-vesting structure contingent on Fox's "continued service through that date and the terms and conditions of the Plan and the applicable award agreement." The expiration date is listed as November 6, 2036.

The filing reports that following this transaction, Fox beneficially owns 139,267 derivative securities directly, with no non-derivative securities reported in Table I. The Form 4 was signed on November 9, 2026 by Justin Hunter on behalf of Jennifer Lynne Fox.

What Was Disclosed

Myriad Genetics' Chief Legal and Corporate Strategy Officer received a retention-based stock option grant of 139,267 shares at $5.92, vesting in full on November 6, 2029, under the company's 2026 equity incentive plan, as reported in a Form 4 filed November 9, 2026.